• Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • Special Issue: Genetics, Genetic Testing, and Biomarkers of Digestive Diseases

Special Issue: Genetics, Genetic Testing, and Biomarkers of Digestive Diseases

A special issue of Gastroenterology features 14 articles discussing the genetic factors that contribute to a range of gastrointestinal (GI),  hepatobiliary, and pancreatic diseases, and how this information can be used in diagnosis and treatment of patients. An introduction to the special issue explains the value of associating diseases with specific genetic variants, which can help

Read more
  • New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

A new test to identify diarrhea-predominant irritable bowel syndrome (D-IBS) and a new class of drugs to treat ulcerative colitis were presented at Digestive Disease Week (DDW) in Washington DC, May 15–19. Researchers also warned that many residents of nursing homes are being inappropriately given proton pump inhibitors (PPIs). Mark Pimentel

Read more

How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?

For patients with chronic Hepatitis C virus infection, high levels of α-fetoprotein after therapy can identify those at risk for hepatocellular carcinoma (HCC), researchers report in the July issue of Clinical Gastroenterology and Hepatology. In persons with chronic HCV infection, lack of sustained virologic response (SVR) 24 weeks after the end

Read more

How Can We Screen for Pancreatic Cancer and its Precursors?

Individuals with invasive pancreatic cancer or high-grade dysplasia can be identified based on a specific DNA mutation in pancreatic juice samples from the duodena, according to the June issue of Clinical Gastroenterology and Hepatology. Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and its precursors.

Read more

Does a Response to Proton Pump Inhibitor Therapy Indicate GERD?

Just because a patient’s upper gastrointestinal symptoms are alleviated by proton pump inhibitors (PPIs) doesn’t necessarily mean that they have gastroesophageal reflux disease (GERD), according to the December issue of Clinical Gastroenterology and Hepatology. The efficacy of PPI therapy often is tested to determine whether patients’ symptoms are acid-related and

Read more

What are the Barriers to CRC Screening?

Waiving copayments for colonoscopy examinations to detect colorectal cancer (CRC) increases the number of patients that undergo screening, according to a study published in the July issue of Clinical Gastroenterology and Hepatology. Colonoscopy is a recommended, cost-effective method of CRC screening that appears to reduce mortality, yet only half of

Read more

Can Imaging Identify the Most Dangerous Pancreatic Cystic Neoplasms?

Endoscopic ultrasound can be used to identify cystic neoplasms of the pancreas that are most likely to become malignant, according to the February issue of Clinical Gastroenterology and Hepatology. Mucus-producing cystic neoplasms of the pancreas, including intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN), that have mural nodules

Read more